AI‑Driven Discovery Expands Hope for Women’s Health: Inside the New Insilico-ASKA Partnership

A new collaboration between Insilico Medicine and ASKA Pharmaceutical is setting the stage for faster, smarter breakthroughs in women’s health. The two companies have expanded their partnership to accelerate the discovery of novel therapeutic targets for some of the most challenging gynecological conditions-endometriosis, uterine fibroids, and adenomyosis-using advanced AI‑powered biological analytics.

What each partner brings

ASKA Pharmaceutical contributes decades of clinical and therapeutic expertise in obstetrics and gynecology.

Insilico Medicine, a leader in generative‑AI drug discovery, brings its proprietary platforms-especially PandaOmics, an AI engine designed to identify high‑potential therapeutic targets from complex biological data.

Together, they aim to uncover new biological pathways and targets that could lead to next‑generation treatments.

Read more via the link